Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Feb 2;77(2):303-309.
doi: 10.1093/jac/dkab404.

Azithromycin in patients with COVID-19: a systematic review and meta-analysis

Luis Ayerbe  1   2 , Carlos Risco-Risco  3 , Ivo Forgnone  4 , Maria Pérez-Piñar  2 , Salma Ayis  5
Affiliations
Meta-Analysis

Azithromycin in patients with COVID-19: a systematic review and meta-analysis

Luis Ayerbe et al. J Antimicrob Chemother. .

Abstract

Background: Azithromycin has been widely used in the management of COVID-19. However, the evidence on its actual effects remains disperse and difficult to apply in clinical settings. This systematic review and meta-analysis summarizes the available evidence to date on the beneficial and adverse effects of azithromycin in patients with COVID-19.

Methods: The PRISMA 2020 statement criteria were followed. Randomized controlled trials (RCTs) and observational studies comparing clinical outcomes of patients treated with and without azithromycin, indexed until 5 July 2021, were searched in PubMed, Embase, The Web of Science, Scopus, The Cochrane Central Register of Controlled Trials and MedRXivs. We used random-effects models to estimate pooled effect size from aggregate data.

Results: The initial search produced 4950 results. Finally, 16 studies, 5 RCTs and 11 with an observational design, with a total of 22 984 patients, were included. The meta-analysis showed no difference in mortality for those treated with or without azithromycin, in observational studies [OR: 0.90 (0.66-1.24)], RCTs [OR: 0.97 (0.87-1.08)] and also when both types of studies were pooled together [with an overall OR: 0.95 (0.79-1.13)]. Different individual studies also reported no significant difference for those treated with or without azithromycin in need for hospital admission or time to admission from ambulatory settings, clinical severity, need for intensive care, or adverse effects.

Conclusions: The results presented in this systematic review do not support the use of azithromycin in the management of COVID-19. Future research on treatment for patients with COVID-19 may need to focus on other drugs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Studies identified at each stage of the search.
Figure 2.
Figure 2.
Forest plot of observational studies and RCTs on the association between treatment with azithromycin and death.
Figure 3.
Figure 3.
Forest plot of observational studies and RCTs on the association between treatment with azithromycin and death (studies by Albani et al. and Wang et al. excluded).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sultana J, Cutroneo PM, Crisafulli S. et al. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf 2020; 43: 691–8. - PMC - PubMed
    1. Gyselinck I, Janssens W, Verhamme P. et al. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res 2021; 8: e000806. - PMC - PubMed
    1. O’Connell TF, Bradley CJ, Abbas AE. et al. Hydroxychloroquine/azithromycin therapy and QT prolongation in hospitalized patients with COVID-19. JACC Clin Electrophysiol 2021; 7: 16–25. - PMC - PubMed
    1. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ. et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143: 225–45. - PubMed
    1. International Prospective Register of Systematic Reviews. (PROSPERO) https://www.crd.york.ac.uk/PROSPERO/.

Publication types